Expected population impacts of discontinued prostate-specific antigen screening.

Publication Type:

Journal Article

Source:

Cancer (2014)

Keywords:

2014, August 2014, Public Health Sciences Division

Abstract:

Prostate-specific antigen (PSA) screening for prostate cancer has high risks of overdiagnosis, particularly among older men, and reports from screening trials indicate that it saves few lives after 11 to 13 years of follow-up. New clinical guidelines recommend against PSA screening for all men or for men aged >70 years, but, to the authors' knowledge, the expected population effects of these guidelines have not been studied to date.